Inloggad som:

MK-7339-007 AGENT

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
MK-7339-007 AGENT
Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 2
Palliativ
Företag

Studien ändrades senast av: studyjohanna (2020-08-25)

Tillbaka till listan